1 – 9 of 9
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Breast cancer survival and incidence of second primary cancers after 30 years in a randomized study of two versus five years of adjuvant tamoxifen therapy
(
- Contribution to journal › Article
- 2020
-
Mark
Efficacy and safety of tailored and dose-dense adjuvant chemotherapy and trastuzumab for resected HER2-positive breast cancer : Results from the phase 3 PANTHER trial
(
- Contribution to journal › Article
- 2018
-
Mark
Long-term safety and survival outcomes from the Scandinavian Breast Group 2004-1 randomized phase II trial of tailored dose-dense adjuvant chemotherapy for early breast cancer
(
- Contribution to journal › Article
- 2017
-
Mark
Long-term effects on the incidence of second primary cancers in a randomized trial of two and five years of adjuvant tamoxifen
(
- Contribution to journal › Article
- 2016
-
Mark
Effect of tailored dose-dense chemotherapy vs standard 3-weekly adjuvant chemotherapy on recurrence-free survival among women with high-risk early breast cancer : A randomized clinical trial
(
- Contribution to journal › Article
- 2013
-
Mark
Effects of adjuvant tamoxifen therapy on cardiac disease: results from a randomized trial with long-term follow-up
(
- Contribution to journal › Article
- 2011
-
Mark
A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer
(
- Contribution to journal › Article
- 2006
-
Mark
TOP2A and HER2 gene amplification as predictors of response to anthracycline treatment in breast cancer
(
- Contribution to journal › Article
- 1982
-
Mark
ASBESTOS EXPOSURE AND MALIGNANT LYMPHOMA
(
- Contribution to journal › Letter